

NEWS RELEASE

<<http://www.takara-bio.co.jp>>

<p>Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan</p>
--

Kusatsu/Shiga, Japan — March 29, 2019 – Takara Bio Inc. (Takara Bio) announced today that a new drug application for marketing approval in Japan has been submitted for C-REV (canerpaturev, former HF10) as a regenerative medicine product for the treatment in patients with unresectable or metastatic melanoma.

This application was based on results from clinical trial of combination treatment with Ipilimumab in patients with unresectable or metastatic melanoma after existing therapy. This development targeting melanoma has been conducted as our initiative project. Based on the exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and sales of C-REV in Japan, Takara Bio and Otsuka will exclusively be responsible for manufacturing and marketing upon the marketing approval, respectively. Takara Bio is striving to address the unmet medical needs and contribute to further increasing the benefits for patients and their families.

This application has no impact on the current fiscal year's financial forecast.